Clinical Trials Directory

Trials / Unknown

UnknownNCT01455649

Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults

A Prospective, Open-label, Controlled, Randomized Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After 90 to 150 Days After Kidney Transplantation in Adults, Maintaining Corticosteroid and Mycophenolate Sodium Compared to Patients Who Will Maintain the Use of Calcineurin Inhibitor

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Deise de Boni Monteiro de Carvalho · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to demonstrate the efficacy and safety in the use of everolimus, with its onset after 3 months of treatment with calcineurin inhibitor.

Detailed description

The patient who met the inclusion and exclusion criteria will be included in the study and randomized into two groups in the third month post transplant, they will be in use of tacrolimus, corticosteroids and Mycophenolate sodium. The group 1 will undergo a conversion from calcineurin inhibitor to Everolimus within 1 day (overnight), group 2 will be maintained with the initial immunosuppression. We will start Everolimus at 1 mg 2x/day and three days after the beginning we will adjust the dose by the serum levels, which will be kept in 6 to 10ng/dL. The doses of corticosteroids and Mycophenolate sodium will be retained. There will be performed renal biopsies at randomization and after 12 months. The glomerular filtration rate will be calculated monthly using the MDRD.

Conditions

Interventions

TypeNameDescription
DRUGEverolimusGroup will switch calcineurin inhibitor to everolimus within 1 day (overnight).
DRUGcalcineurin inhibitorGroup will maintain their initial immunosuppression therapy with calcineurin inhibitor

Timeline

Start date
2011-11-01
Primary completion
2013-11-01
Completion
2013-11-01
First posted
2011-10-20
Last updated
2011-10-20

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT01455649. Inclusion in this directory is not an endorsement.